Drug Profile

NeoTCR P201

Alternative Names: NeoTCR-P201

Latest Information Update: 05 Aug 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PACT Pharma
Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Preclinical Bladder cancer; Breast cancer; Colorectal cancer; Head and neck cancer; Lung cancer; Ovarian cancer; Prostate cancer; Skin cancer

20 Jul 2022 Preclinical trials in Bladder cancer in USA (Parenteral) (PACT Pharma pipeline, July 2022)
20 Jul 2022 Preclinical trials in Breast cancer in USA (Parenteral) (PACT Pharma pipeline, July 2022)
20 Jul 2022 Preclinical trials in Colorectal cancer in USA (Parenteral) (PACT Pharma pipeline, July 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com